[Activity of sacituzumab govitecan in skin metastases: description of a case.]

Abstract

Advanced triple-negative breast cancer is characterized by a severe prognosis, poor response to conventional therapies and poses multiple challenges for the medical oncologist. However, recent developments in molecular research and targeted therapy are opening up new perspectives with encouraging results for the treatment of this aggressive disease. The shared case wants to be an example: we will discuss the story of a 54 years old woman with extensive metastatic localizations in the skin that has obtained an important clinical response to therapy with sacituzumab govitecan, a conjugate antibody approved for the treatment of adult patients with metastatic triple negative breast cancer.